YB1-X7 / Shaoxing Salvectors Biotechnology - LARVOL DELTA

Safety and Preliminary Efficacy of YB1-X7, a Synthetic Biology-Engineered Hypoxia-Targeting Oncolytic Bacterium, as Monotherapy or Combined with Toripalimab in Advanced Solid Tumors (ESMO 2026) - No abstract available

Clinical • Metastases • Monotherapy • Oncology • Solid Tumor

Safety and Efficacy of YB1‑X7 Injection in Patients with Advanced Hepatocellular Carcinoma after Failure of First‑Line Therapy: A Single‑Arm, Open‑Label, Exploratory IIT (Phase I+II) Clinical Study (ChiCTR) - P1/2 | N=42 | Not yet recruiting | Sponsor: Shanghai General Hospital; SHANGHAI GENERAL HOSPITAL

New P1/2 trial • Hepatocellular Cancer • Oncology • Solid Tumor